SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile
BackgroundEsketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic si...
Saved in:
| Main Authors: | Ying Xiao, Xuefeng Hu, Wei Xing, Jie Yan, Ruhuan Wang, Xiaoqing Li, Jiahuan Li, Zhixin Zhang, Jingchao Sun, Junjun Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1464564/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of dextromethorphan-bupropion exposures compared with exposures involving dextromethorphan alone or bupropion alone reported to United States poison centers
by: Sonia Ngo, et al.
Published: (2025-12-01) -
Can dextromethorphan-bupropion reduce mental pain in depressed individuals? A hypothesis-generating overview perspective
by: Maurizio Pompili, et al.
Published: (2025-03-01) -
Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD)
by: Ranjan Das, et al.
Published: (2025-06-01) -
Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment‐resistant depression and psychiatric comorbidities
by: Bruno Pedraz‐Petrozzi, et al.
Published: (2023-03-01) -
Sustainable spectrophotometric determination of dextromethorphan and bupropion: A fourier self-deconvolution approach
by: Fotouh R. Mansour, et al.
Published: (2025-06-01)